TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00881491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Double Antibiotic Paste
Description: ciprofloxacin and metronidazole powder mixed at a 1:1 ratio used as a intracanal medicament for disinfection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple Antibiotic Paste
Description: ciprofloxacin, metronidazole \& minocycline mixed to a 1:1:1 powder used as a intracanal medicament for disinfection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mineral Trioxide Aggregate
Description: standard material providing an apical barrier
Study: NCT03997513

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pulmonary Telerehabilitation
Description: The intervention will consist of an eight-week, three sessions per week, home-based pulmonary telerehabilitation program that will incorporate both lower extremity endurance exercise and upper and lower extremity resistance training. Subjects randomized to the study intervention will also participate in a one hour, twice-monthly support group via group video conferencing consisting of an educational topic (i.e. inhaler use, understanding COPD) and group discussion.
Study: NCT02904616

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mobile spectrofluorimeter
Study: NCT04493125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosapride citrate
Description: Patients receive mosapride citrate (5mg/T) three times a day from the first day after surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03338790

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzalutamide
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rucaparib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Specified dose on specified days
Study: NCT02393287

Intervention type: OTHER
Intervention: Eribulin (ReProLine)
Description: this is an observational trial ; there is no intervention
Study: NCT04425018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Pre-determined dose administered via IV, Day 1,8,15 of each cycle 4 study cycles, or 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Pre-determined dose administered via IV, Day 1,8,15 of each cycle 4 study cycles, or 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pre-determined dose administered via IV - Day 1 of each 21- day cycle 4 study cycles, or 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pre-determined dose administered via IV - Day 1 of each 21- day cycle 4 study cycles, or 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Margetuximab
Description: Pre-determined dose administered by IV - Day 1 of each 21- day cycle 4 study cycles, or 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Pre-determined dose administered via IV Day 1 of each 21- day cycle for 4 study cycles, or 12 weeks.
Study: NCT03506308

Intervention type: DEVICE
Group type: OTHER
Intervention: LUTONIX 035 Drug Coated Balloon PTA Catheter
Description: All subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.
Study: NCT03045848

Intervention type: DEVICE
Intervention: Biofreedom drug-coated stent
Description: BioFreedom (Biosensors International Technologies, Singapore) is the only polymer- and carrier-free drug coated stent with Biolimus A9 in a selectively micro-structured abluminal surface. It is a stainless steel bare metal surface with 120 micron thick corrugated ring strut.
Study: NCT03569384

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Tele Rehab
Description: The intervention group will obtain telerehabilitation

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Tele Rehab
Description: The intervention group will obtain telerehabilitation
Study: NCT01446484

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD4+CD25+CD127lowFoxP3+ T regulatory cells injection
Description: Blood samples from patients in the experimental group will be collected twice with weekly interval in the amount of 70 ml/1,73 m2. T cells CD4+ will be separated from blood samples and frozen in liquid nitrogen. At day 30 after transplantation patients will undergo subcutaneous injection of approximately 2x 10\^8 autologous T regs, expanded from previously frozen CD4+ T cells. Levels of T reg cells in patient's blood will be estimated by flow cytometry in a week after injection. That cell injection procedure will be repeated at 6 months after transplantation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alemtuzumab
Description: Immunosuppressant; 2 doses of drug by intravenous infusion on Days 14 - 21 before Tx and on Day 0 after Tx

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Immunosuppressant; 2 doses of drug by intravenous infusion on Days 14 - 21 before Tx and on Day 0 after Tx

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: Immunosuppressant; oral daily dose starting Day 2-3 until withdrawal or end of the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Immunosuppressant; oral daily dose starting Day 2-3 until withdrawal or end of the study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Immunosuppressant; oral daily dose starting no earlier then after Month 1 post-transplant until withdrawal or end of the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Immunosuppressant; oral daily dose starting no earlier then after Month 1 post-transplant until withdrawal or end of the study
Study: NCT01497483

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin alone
Description: Pravastatin 40 mg with placebo.
Study: NCT01446484

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Immunosuppressant; daily dose starting Day 0 until withdrawal or end of the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Immunosuppressant; daily dose starting Day 0 until withdrawal or end of the study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: Immunosuppressant; daily dose starting Day 0 until withdrawal or end of the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Immunosuppressant; daily dose starting Day 0 until withdrawal or end of the study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Immunosuppressant; oral daily dose starting no earlier then after Month 1 post-transplant until withdrawal or end of the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Immunosuppressant; oral daily dose starting no earlier then after Month 1 post-transplant until withdrawal or end of the study

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Kidney transplantation
Description: Living related kidney transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kidney transplantation
Description: Living related kidney transplantation
Study: NCT03490201

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Market Approved RF Ablation System
Description: Subjects receive ablation using an FDA approved radiofrequency (RF) ablation system.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FlexAbility SE Ablation Catheter
Description: Subjects receive ablation treatment using an ablation system that is not FDA approved.
Study: NCT05809245

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corneal neurotization
Description: Autologous sural nerve will be harvested or cadaveric nerve graft will be coapted to an intact sensory branch of the trigeminal nerve. The nerve will be separated into fascicles which will be tunneled under the conjunctiva around the cornea near the limbus.
Study: NCT01497483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin and Cyclosporine
Description: Pravastatin 40 mg co-administered with 200 mg of cyclosporine.
Study: NCT01548872

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HTK solution
Description: 50 ml/kg bolus in 2 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: crystalloid cardioplegia solution
Description: 30 ml/kg bolus in two minutes
Study: NCT01076803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide (acetate)
Description: Deep subcutaneous injection into the upper external quadrant of the right or the left buttock.
Study: NCT01144884

Intervention type: OTHER
Group type: OTHER
Intervention: Procedure (education and exercise)
Description: education/exercise
Study: NCT03083483

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS)
Description: tDCS will apply a low, direct current for the duration of the study session while the subject is training the specific laparoscopic tasks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS)
Description: tDCS will apply a low, direct current for the duration of the study session while the subject is training the specific laparoscopic tasks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation (tDCS)
Description: tDCS will apply a low, direct current for the duration of the study session while the subject is training the specific laparoscopic tasks.
Study: NCT02012647

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Participants sit in a chair that looks like one in a dentist's office. A magnetic coil will be placed on the scalp on one side of the head, overlying the brain's motor cortex to stimulate the brain's output to the muscles in the opposite hand. A second magnetic coil will be placed on the scalp of the opposite side. Recordings from both hands will be made using the magnetic coils placed on scalp. Results will be compared for participants with and without Parkinson's Disease.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Participants sit in a chair that looks like one in a dentist's office. A magnetic coil will be placed on the scalp on one side of the head, overlying the brain's motor cortex to stimulate the brain's output to the muscles in the opposite hand. A second magnetic coil will be placed on the scalp of the opposite side. Recordings from both hands will be made using the magnetic coils placed on scalp. Results will be compared for participants with and without Parkinson's Disease.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Motor Physiology Testing
Description: Participants will be asked to move their upper and lower limbs while seated in a chair. Wireless EMG sensors placed on arm and leg muscles will record measurements during this procedure. Upper and lower limb testing will be performed separately.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Motor Physiology Testing
Description: Participants will be asked to move their upper and lower limbs while seated in a chair. Wireless EMG sensors placed on arm and leg muscles will record measurements during this procedure. Upper and lower limb testing will be performed separately.
Study: NCT06543147

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breast cancer and breast self- examination education
Description: The experimental group were given education about breast cancer and BSE. Slide presentations used during training provided information about breast anatomy and physiology, breast cancer symptoms and risk factors, early diagnosis methods for breast cancer and breast cancer screening programs, and barriers to breast cancer screening programs were discussed. In addition to slide presentations about breast cancer and BSE, women were also given BSE training on a breast examination mannequin and given brochures after training. The training lasted 40-50 minutes. After women in the experimental group were given training, they were called by telephone once per month until 6 months and reminded about doing BSE.
Study: NCT03490201

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FlexAbility SE Ablation Catheter
Description: Subjects receive ablation treatment using an ablation system that is not FDA approved.
Study: NCT03683420

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: The intervention consists of using an iPod to listen to music for up to 60 minutes while patients are receiving chemo infusion. There are no on components to the study.
Study: NCT03252847

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: AAV5-RPGR
Description: Single, subretinal administration of AAV5-RPGR

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: AAV5-RPGR
Description: Single, subretinal administration of AAV5-RPGR
Study: NCT02733003

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Women's Health CoOp (WHC)
Description: Participants in this group will participate in two workshops of the woman-focused intervention about HIV/STIs, sexual behaviors, alcohol and other drug use, violence, communication skills, and other issues.
Study: NCT02028234

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole,
Description: os, 20 mg, once per day, for 30 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole,
Description: os, 20 mg, once per day, for 30 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: os, 20 mg, once per day, for 30 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: os, 20 mg, once per day, for 30 days
Study: NCT03246256

Intervention type: OTHER
Intervention: Group 1

Intervention type: OTHER
Intervention: Group 1
Study: NCT02503423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX660
Description: described above

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX660
Description: described above

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX660
Description: described above

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX660
Description: described above

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX660
Description: described above

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX660
Description: described above

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX660
Description: described above

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX660
Description: described above

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX660
Description: described above
Study: NCT03836079

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: preCARDIA system
Description: Intermittent occlusion of the SVC
Study: NCT04882241

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Oral tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capecitabine
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5-fluorouracil
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5-fluorouracil
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxaliplatin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Leucovorin
Description: IV infusion
Study: NCT01368900

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ulthera® System treatment
Description: Focused ultrasound energy delivered below the surface of the skin.
Study: NCT04590534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chromax
Description: Treatment of BPH by Chromax for 3 Months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildosin Group
Description: patients will receive one capsule of Sidosin 8 mg once daily for 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group
Description: patients will receive placebo 3 times daily for 12 weeks
Study: NCT00005810

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estramustine phosphate sodium
Study: NCT04027348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide
Description: Given IV
Study: NCT04104451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corlicyte
Description: expanded umbilical cord lining mesenchymal stem cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corlicyte
Description: expanded umbilical cord lining mesenchymal stem cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corlicyte
Description: expanded umbilical cord lining mesenchymal stem cells
Study: NCT03943966

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 18F-GP1 PET CT
Description: PET CT scan using platelet radiotracer 18F-GP1

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-GP1 PET CT
Description: PET CT scan using platelet radiotracer 18F-GP1

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 18F-GP1 PET CT
Description: PET CT scan using platelet radiotracer 18F-GP1

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 18F-GP1 PET CT
Description: PET CT scan using platelet radiotracer 18F-GP1

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 18F-GP1 PET CT
Description: PET CT scan using platelet radiotracer 18F-GP1
Study: NCT04737902

Intervention type: PROCEDURE
Intervention: Erector spinae plane block
Description: Unilateral ESP block was performed between T3 and T7 levels depending on the thoracic surgical incision. The patient is placed in lateral decubitus position, under sterile conditions, a high frequency (6-15 MHz) linear-array transducer (Sonosite® Edge II, Bothell, USA) was placed in a longitudinal parasagittal orientation 2 cm from the posterior midline to visualise the tips of the transverse processes deep to the erector spinae muscle (ESM). A 21 G, 50 mm or 100 mm needle (Pajunk UniPlex NanoLine; Germany) was advanced in-plane with the ultrasound beam. The needle tip was directed to the plane between the transverse process and the posterior fascia of the ESM. Correct needle tip location was confirmed by ultrasound visualisation of linear fluid spread in the fascial plane. The injection of 0.5 to 1 ml of bupivacaine was 0.5% with epinephrine 5 µg/ml; then, a total of 20-30 ml of the same local anaesthetic was administered.
Study: NCT04247659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium aescinate
Description: The main mechanism of sodium aescinate includes anti - inflammatory, anti - exudate anti - oxygen free radical ,anti - edema increased venous tension.The treatment course of sodium aescinate is 10 days,20mg/day, intravenous infusion.
Study: NCT02475603

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty
Description: Total knee arthroplasty

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty
Description: Total knee arthroplasty
Study: NCT02277743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Subcutaneous injection alternated among the different quadrants of the abdomen, upper thighs and upper arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Subcutaneous injection alternated among the different quadrants of the abdomen, upper thighs and upper arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for Dupilumab)
Description: Subcutaneous injection alternated among the different quadrants of the abdomen, upper thighs and upper arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for Dupilumab)
Description: Subcutaneous injection alternated among the different quadrants of the abdomen, upper thighs and upper arms
Study: NCT01224158

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental Power Toothbrush
Description: Following a placebo mouthwash phase, Subjects will be asked to brush their teeth (twice per day with the experimental toothbrush and toothpaste provided) moving to the next quadrant of the mouth at 30-second intervals.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flat trimmed Manual Toothbrush
Description: Following a placebo mouthwash phase, Subjects will be asked to brush their teeth (twice per day using the toothbrush and toothpaste provided) in their usual manner.